Biotech Values

[DewDiligence]

Big Pharma’s % of Sales from US Pharma

Below are Citigroup’s estimates for the percentage of each Big Pharma’s 2010 corporate-wide sales that come from US branded prescription drugs. NVS, at 16%, is the lowest of any Big Pharma. (I think Citi’s 16% figure is a little too low and prefer my own estimate of 20% in #msg-49251301, but this is splitting hairs.)

Note that all of these companies except BMY and NVO have non-pharma business segments. (MRK’s % of sales from US pharma was much higher before it merged with SGP; PFE’s % was higher before it merged with WYE.)

BMY 64%
LLY 53%
AZN 40%
MRK 37%
PFE 37%
NVO 36%
Roche 32%
GSK 30%
ABT 26%
JNJ 21%
SNY 20%
NVS 16%

Source:
http://www.ft.com/cms/s/0/71c84832-639d-11df-a32b-00144feab49a.html
(the ft.com article that’s the source of the quiz in #msg-50508007).